Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
| Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | |||
| Iluvien | fluocinolone acetonide intravitreal implant | diabetic macular edema | Do not reimburse | Complete | ||
| Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ilaris | Canakinumab | Cryopyrin-Associated Periodic Syndrome | Do not list | Complete | ||
| Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete |
Last Updated : May 3, 2024